CSER Phase 2 Provider Return of Results Follow-up #1 Survey is administered 0-6 weeks post-return of results to providers of research participants that were returned positive, negative, VUS, and se
CSER Phase 2 Provider Return of Results Follow-up #2 Survey is administered at 5-7 months post-return of results, regardless of whether the provider has completed the CSER Phase 2 Provider Return o
This published study protocol for the MedSeq trials includes a description of the study design; recruitment, enrollment, and sample size plan; patient exclusion/inclusion criteria; and process of i
CSER Phase 1: The Institutional and Professional Impact of Genomic Sequencing in Cancer Care Study Protocol
This document is the study protocol of the Institutional and Professional Impact of Genomic Sequencing in Cancer Care study.
A pre- and post-test questionnaire that measures changes in the knowledge and attitudes of physicians who have been administered pharmacogenetic testing is available in the supporting information s
Lee, K. H., Min, B. J., & Kim, J. H. (2019). Personal genome testing on physicians improves attitudes on pharmacogenomic approaches. PloS One, 14(3), e0213860.
Goisef and colleagues developed a survey for professionals working in research-based biobanks in Europe that assess their satisfaction with current ELSI-related procedures.
Goisauf, M., Martin, G., Bentzen, H. B., Budin-Ljøsne, I., Ursin, L., Durnová, A., Leitsalu, L., Smith, K., Casati, S., Lavitrano, M., Mascalzoni, D., Boeckhout, M., Mayrhofer, M. Th. (2019) Data in question: A survey of European biobank professionals on ethical, legal and societal challenges of biobank research. PLoS ONE 14(9): e0221496.